In summary, AGP-HA NPs inhibit the ability of inflammation to attenuate breast cancer cell migration, providing a promising nanotherapeutic platform for the treatment of breast cancer (Omar et al., 2022). This evidence concerns the gene ATP5MK and breast carcinoma.